Andriole GL - Search Results

1

Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?

Tombal B, Andriole GL, de la Taille A, Gontero P, Haese A, Remzi M, Speakman M, Smets L, Stoevelaar H. Tombal B, et al. Among authors: andriole gl. Urology. 2013 May;81(5):998-1004. doi: 10.1016/j.urology.2012.11.069. Epub 2013 Mar 21. Urology. 2013. PMID: 23523291 Free article. Clinical Trial.

2

The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.

Evans CP, Higano CS, Keane T, Andriole G, Saad F, Iversen P, Miller K, Kim CS, Kimura G, Armstrong AJ, Sternberg CN, Loriot Y, de Bono J, Noonberg SB, Mansbach H, Bhattacharya S, Perabo F, Beer TM, Tombal B. Evans CP, et al. Eur Urol. 2016 Oct;70(4):675-683. doi: 10.1016/j.eururo.2016.03.017. Epub 2016 Mar 19. Eur Urol. 2016. PMID: 27006332 Clinical Trial.

3

Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.

Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster RS, Andriole GL, Groskopf J. Aubin SM, et al. Among authors: andriole gl. Urology. 2011 Aug;78(2):380-5. doi: 10.1016/j.urology.2011.03.033. Urology. 2011. PMID: 21820580

4

Prevention and early detection of prostate cancer.

Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Dräger BJ, Schröder FH, Stenzl A, Tombal B, Wilt TJ, Wolk A. Cuzick J, et al. Lancet Oncol. 2014 Oct;15(11):e484-92. doi: 10.1016/S1470-2045(14)70211-6. Lancet Oncol. 2014. PMID: 25281467 Free PMC article. Review.

5

Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.

Moreira DM, Bostwick DG, Andriole GL, Peterson BL, Cohen HJ, Castro-Santamaria R, Freedland SJ. Moreira DM, et al. Among authors: andriole gl. J Urol. 2015 Nov;194(5):1241-6. doi: 10.1016/j.juro.2015.05.103. Epub 2015 Jul 10. J Urol. 2015. PMID: 26165588 Clinical Trial.

6

The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.

Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F, Pettaway C, Tammela TL, Teloken C, Tindall D, Freedland SJ, Somerville MC, Wilson TH, Fowler I, Castro R, Rittmaster RS; REDUCE Study Group. Andriole GL, et al. J Urol. 2011 Jan;185(1):126-31. doi: 10.1016/j.juro.2010.09.011. Epub 2010 Nov 12. J Urol. 2011. PMID: 21074214 Clinical Trial.

7

Does Obesity Modify the Ability of Prebiopsy Prostate Specific Antigen to Detect Prostate Cancer on Repeat Biopsy? Results from the REDUCE Study.

Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ. Vidal AC, et al. Among authors: andriole gl. J Urol. 2015 Jul;194(1):52-7. doi: 10.1016/j.juro.2015.01.111. Epub 2015 Feb 7. J Urol. 2015. PMID: 25661298 Clinical Trial.

8

The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.

Jamnagerwalla J, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ. Jamnagerwalla J, et al. Among authors: andriole gl. J Urol. 2016 Sep;196(3):715-20. doi: 10.1016/j.juro.2016.03.172. Epub 2016 Apr 5. J Urol. 2016. PMID: 27060053 Free PMC article. Clinical Trial.

9

Extent of Baseline Prostate Atrophy Is Associated With Lower Incidence of Low- and High-grade Prostate Cancer on Repeat Biopsy.

Freitas DM, Andriole GL Jr, Castro-Santamaria R, Freedland SJ, Moreira DM. Freitas DM, et al. Among authors: andriole gl jr. Urology. 2017 May;103:161-166. doi: 10.1016/j.urology.2016.12.027. Epub 2016 Dec 23. Urology. 2017. PMID: 28024967

10

PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.

Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster R, Andriole GL, Groskopf J. Aubin SM, et al. Among authors: andriole gl. J Urol. 2010 Nov;184(5):1947-52. doi: 10.1016/j.juro.2010.06.098. Epub 2010 Sep 17. J Urol. 2010. PMID: 20850153

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

428 results

Search Page

Filters